Kari Adams Torp, MD
Internal Medicine
Sees patients age 18 and up
Penn Internal Medicine Radnor
Penn Medicine Provider

About me

  • Clinical Assistant Professor of Medicine (General Internal Medicine)

Education and training

  • Medical School: Temple University
  • Residency: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

1571 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
she is excellent
November 2025
listens to patients concerns
October 2025
excellent care
October 2025
she is a great doctor

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Torp is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Banerjee, R., Ibrahim, KD., Swed, B., Torp, K., Srinath, A., Buckley, R., Bird, A., & Myers, JS. Transforming Patient Safety Education for Trainees Using Miller's Pyramid as a Framework. , HUP Department of Medicine Research Day: 2018


Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. , Pediatr Blood Cancer., 62(7): 2015,1184-1189


Seif AE, Walker DM, Li Y, Huang YS, Kavcic M, Torp K, Bagatell R, Fisher BT, Aplenc R. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. , Pediatr Blood Cancer., 62(4): 2015,704-709


Fisher BT, Sammons JS, Li Y, de Blank P, Seif AE, Huang YS, Kavcic M, Klieger S, Harris T, Torp K, Rheam D, Shah A, Aplenc R. Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. , J Pediatric Infect Dis Soc., 3(4): 2014,329-335


Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YS, Harris T, Shah A, Hall M, Fieldston ES, Kavcic M, Vujkovic M, Bailey LC, Kersun LS, Reilly AF, Rheingold SR, Walker DM, Aplenc R. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. , Pediatr Blood Cancer., 6(5): 2014,846-852


Fisher BT, Kavcic M, Li Y, Seif AE, Bagatell R, Huang YS, Zaoutis T, Torp K, Leckerman KH, Aplenc R. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia. , Clin Infect Dis., 58(4): 2014,502-508


Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang YS, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc R. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. , Pediatr Crit Care Med., 15(2): 2014,112-120


Fisher BT, Harris T, Torp K, Seif AE, Shah A, Huang Yuan-Shung V, Bailey LC, Kersun LS, Reilly AF, Rheingold SR, Walker D, Li Yi, Aplenc R. Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data. , Medical care., 52(1): 2014,e1-6


Lothstein K, Fisher B, Li Y, Seif A, Harris T, Torp K, Kavcic M, Huang YS, Rheingold SR, Aplenc R. Zoonotic infections in pediatric patients with acute leukemia. , Pediatr Blood Cancer., 60(12): 2013,e160-2


Fisher BT, Gerber JS, Leckerman KH, Seif AE, Huang YS, Li Y, Harris T, Torp K, Douglas R, Shah A, Walker D, Aplenc R. Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. , Leuk Lymphoma., 54(8): 2013,1633-39